Tvardi Therapeutics
TVRD
133 hedge funds and large institutions have $426M invested in Tvardi Therapeutics in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 43 reducing their positions, and 32 closing their positions.
43% more call options, than puts
Call options by funds: $6.31M | Put options by funds: $4.4M
0.05% more ownership
Funds ownership: 1.87% → 1.92% (+0.05%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12% less funds holding
Funds holding: 151 → 133 (-18)
14% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 43
16% less capital invested
Capital invested by funds: $505M → $426M (-$79.1M)
44% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$13.3M |
| 2 |
O
OrbiMed
New York
|
+$8.95M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$8.33M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$7.29M |
| 5 |
D.E. Shaw & Co
New York
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.95M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$1.45M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.34M |
| 5 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
-$1.24M |
TVRD Hedge Fund Activity: Q1 2020 in Review
133 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2020, worth a combined $426M — down 16% from $505M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of TVRD and 18 opened new positions — a net loss of 14 holders — while 43 trimmed existing stakes and 37 added.
The largest buyer was Carmignac Gestion, adding an estimated $13.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $12M.
- 133 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2020, down from 151 in Q4 2019.
- Funds reported $426M of Tvardi Therapeutics stock for Q1 2020, down 16% quarter-over-quarter.
- 18 funds opened new Tvardi Therapeutics positions in Q1 2020 and 32 closed out, a net change of -14 holders.
- The largest Tvardi Therapeutics buyer in Q1 2020 was Carmignac Gestion, an estimated $13.3M added.
- The largest Tvardi Therapeutics seller in Q1 2020 was T. Rowe Price Associates, an estimated $12M sold.
Based on aggregated 13F filings for Q1 2020.